NZ701652A - Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression - Google Patents
Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expressionInfo
- Publication number
- NZ701652A NZ701652A NZ701652A NZ70165213A NZ701652A NZ 701652 A NZ701652 A NZ 701652A NZ 701652 A NZ701652 A NZ 701652A NZ 70165213 A NZ70165213 A NZ 70165213A NZ 701652 A NZ701652 A NZ 701652A
- Authority
- NZ
- New Zealand
- Prior art keywords
- prediction
- gene expression
- progesterone receptor
- response
- breast cancer
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 5
- 230000000708 anti-progestin effect Effects 0.000 title abstract 2
- 239000003418 antiprogestin Substances 0.000 title abstract 2
- 102000003998 progesterone receptors Human genes 0.000 title abstract 2
- 108090000468 progesterone receptors Proteins 0.000 title abstract 2
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101150010487 are gene Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
- C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639407P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/032677 WO2013162776A1 (en) | 2012-04-27 | 2013-03-15 | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ701652A true NZ701652A (en) | 2016-09-30 |
Family
ID=48045769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701652A NZ701652A (en) | 2012-04-27 | 2013-03-15 | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10501800B2 (enExample) |
| EP (1) | EP2841594A1 (enExample) |
| JP (1) | JP2015516155A (enExample) |
| KR (1) | KR20150028232A (enExample) |
| AU (1) | AU2013252913A1 (enExample) |
| CA (1) | CA2871590A1 (enExample) |
| HK (1) | HK1208057A1 (enExample) |
| IL (1) | IL235351A0 (enExample) |
| MX (1) | MX2014013044A (enExample) |
| NZ (1) | NZ701652A (enExample) |
| PH (1) | PH12014502410A1 (enExample) |
| RU (1) | RU2014147625A (enExample) |
| WO (1) | WO2013162776A1 (enExample) |
| ZA (1) | ZA201407853B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013162776A1 (en) | 2012-04-27 | 2013-10-31 | Lange Carol | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
| US20140363425A1 (en) * | 2013-03-13 | 2014-12-11 | J. Dinny Graham | Systems and methods for identifying cancers having activated progesterone receptors |
| US20150276767A1 (en) * | 2014-03-12 | 2015-10-01 | The University Of Sydney | Systems and methods for identifying cancers having activated progesterone receptors |
| RU2017112748A (ru) | 2014-11-17 | 2018-12-19 | Арно Терапьютикс, Инк. | Композиции онапристона пролонгированного действия и способы |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| HK1255104A1 (zh) | 2015-12-15 | 2019-08-02 | Context Biopharma Inc. | 无定形的奥那司酮组合物及其制备方法 |
| WO2018102369A1 (en) | 2016-11-30 | 2018-06-07 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| US10942183B2 (en) | 2017-04-05 | 2021-03-09 | Regents Of The University Of Minnesota | Methods of detecting progesterone receptor and of detecting an expression level |
| EP3822368A1 (en) | 2019-11-14 | 2021-05-19 | Koninklijke Philips N.V. | Assessment of pr cellular signaling pathway activity using mathematical modelling of target gene expression |
| IL296568A (en) * | 2020-03-17 | 2022-11-01 | Regeneron Pharma | Methods and systems for determining responders to treatment |
| JP7619556B2 (ja) * | 2020-10-08 | 2025-01-22 | 藤倉化成株式会社 | 動脈病変を検出し、並びに、脳心臓血管障害、糖尿病、慢性腎臓病、又は固形癌を検出する、体液抗体バイオマーカー |
| US20250005743A1 (en) * | 2023-06-30 | 2025-01-02 | Mackay Memorial Hospital | Method and system for identifying hormone receptor status |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6750015B2 (en) * | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| WO2002000618A2 (en) | 2000-06-28 | 2002-01-03 | University Technology Corporation | Progesterone receptor-regulated gene expression and methods related thereto |
| WO2013162776A1 (en) | 2012-04-27 | 2013-10-31 | Lange Carol | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression |
-
2013
- 2013-03-15 WO PCT/US2013/032677 patent/WO2013162776A1/en not_active Ceased
- 2013-03-15 AU AU2013252913A patent/AU2013252913A1/en not_active Abandoned
- 2013-03-15 RU RU2014147625A patent/RU2014147625A/ru not_active Application Discontinuation
- 2013-03-15 CA CA2871590A patent/CA2871590A1/en not_active Abandoned
- 2013-03-15 EP EP13714144.6A patent/EP2841594A1/en not_active Withdrawn
- 2013-03-15 MX MX2014013044A patent/MX2014013044A/es unknown
- 2013-03-15 HK HK15108666.9A patent/HK1208057A1/xx unknown
- 2013-03-15 US US13/843,482 patent/US10501800B2/en active Active
- 2013-03-15 KR KR20147033298A patent/KR20150028232A/ko not_active Withdrawn
- 2013-03-15 JP JP2015508975A patent/JP2015516155A/ja active Pending
- 2013-03-15 NZ NZ701652A patent/NZ701652A/en not_active IP Right Cessation
-
2014
- 2014-10-27 IL IL235351A patent/IL235351A0/en unknown
- 2014-10-27 PH PH12014502410A patent/PH12014502410A1/en unknown
- 2014-10-28 ZA ZA2014/07853A patent/ZA201407853B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014147625A (ru) | 2016-06-20 |
| HK1208057A1 (en) | 2016-02-19 |
| KR20150028232A (ko) | 2015-03-13 |
| MX2014013044A (es) | 2015-06-23 |
| US10501800B2 (en) | 2019-12-10 |
| ZA201407853B (en) | 2015-12-23 |
| WO2013162776A1 (en) | 2013-10-31 |
| PH12014502410A1 (en) | 2015-01-12 |
| EP2841594A1 (en) | 2015-03-04 |
| CA2871590A1 (en) | 2013-10-31 |
| JP2015516155A (ja) | 2015-06-11 |
| AU2013252913A1 (en) | 2014-11-27 |
| US20130316992A1 (en) | 2013-11-28 |
| IL235351A0 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502410A1 (en) | Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression | |
| MX2023002251A (es) | Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| GB2531881A (en) | Method of isolating circulating tumor cells | |
| WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
| EA201390762A1 (ru) | Новые биомаркеры для предсказания исхода противораковой иммунотерапии | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| MX2019004193A (es) | Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer. | |
| MX2019000091A (es) | Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama. | |
| MY176706A (en) | Biomarkers and methods of treating pd-1 and pd-l1 related conditions | |
| MX2013003077A (es) | Diagnostico de cancer de mama. | |
| MX2015018051A (es) | Expresión génica basada en arnm para personalizar la terapia del cáncer al paciente con un antagonista de mdm2. | |
| WO2013025952A3 (en) | Methods and compositions for the treatment and diagnosis of breast cancer | |
| WO2011153545A3 (en) | Gene expression signature as a predictor of chemotherapeutic response in breast cancer | |
| WO2008106175A3 (en) | Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors | |
| NZ603780A (en) | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer | |
| UA118248C2 (uk) | Інгібітори глюкозилцерамідсинтази | |
| HK1209673A1 (en) | Using modulators of ccr5 for treating cancer | |
| PH12015500388A1 (en) | Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells | |
| BR112015022977A2 (pt) | métodos para predição de risco de metástase em melanoma cutâneo | |
| WO2012138691A3 (en) | Diagnosis and treatment of taxane-resistant cancers | |
| IN2014DN08312A (enExample) | ||
| WO2015181555A8 (en) | Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent | |
| WO2014023808A3 (en) | Method for evaluating a cancer patient for propensity to respond to a therapy | |
| WO2012019125A3 (en) | Biomarkers for prostate cancer and methods for their detection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: BREAST CANCER PROGNOSIS, PREDICTION OF PROGESTERONE RECEPTOR SUBTYPE AND]PREDICTION OF RESPONSE TO ANTIPROGESTIN TREATMENT BASED ON GENE EXPRESSION; FILING DATE: 04 NOV 2014; STATUS: REJECTED; TITLE: BREAST CANCER PROGNOSIS, PREDICTION OF PROGESTERONE RECEPTOR SUBTYPE AND]PREDICTION OF RESPONSE TO ANTIPROGESTIN TREATMENT BASED ON GENE EXPRESSION; FILING DATE: 04 NOV 2014; STATUS: PROPOSED; Effective date: 20150918 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 MAR 2018 BY COMPUTER PACKAGES INC Effective date: 20170218 |
|
| LAPS | Patent lapsed |